Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RECQL4 affects MHC class II-mediated signalling and favours an immune-evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma.
Egea-Rodriguez S, Váraljai R, Nordmann TM, Lubis R, Philip M, Rambow F, Roesch A, Flaig M, Horn S, Stoll R, Zhao F, Paschen A, Klebl B, Hickson ID, Schadendorf D, Mann M, Helfrich I. Egea-Rodriguez S, et al. Among authors: paschen a. Clin Transl Med. 2025 Jan;15(1):e70094. doi: 10.1002/ctm2.70094. Clin Transl Med. 2025. PMID: 39812592 Free PMC article.
Single-cell transcriptomics and epigenomics point to CD58-CD2 interaction in controlling primary melanoma growth and immunity.
Stubenvoll A, Schmidt M, Moeller J, Chango MAL, Schultz C, Antoniadou O, Loeffler-Wirth H, Bernhart S, Große F, Thier B, Paschen A, Anderegg U, Simon JC, Ziemer M, Schoeder CT, Binder H, Kunz M. Stubenvoll A, et al. Among authors: paschen a. Cancer Commun (Lond). 2025 Jan 15. doi: 10.1002/cac2.12651. Online ahead of print. Cancer Commun (Lond). 2025. PMID: 39812166 No abstract available.
Spatial proteomics reveals sirtuin 1 to be a determinant of T-cell infiltration in human melanoma.
Placke JM, Bottek J, Váraljai R, Shannan B, Scharfenberg S, Krisp C, Spangenberg P, Soun C, Siemes D, Borgards L, Hoffmann F, Zhao F, Paschen A, Schlueter H, von Eggeling F, Helfrich I, Rambow F, Ugurel S, Tasdogan A, Schadendorf D, Engel DR, Roesch A. Placke JM, et al. Among authors: paschen a. Br J Dermatol. 2024 Dec 31:ljae433. doi: 10.1093/bjd/ljae433. Online ahead of print. Br J Dermatol. 2024. PMID: 39739311
Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
Lodde GC, Zhao F, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Jansen P, Kowall B, Galetzka W, Hörst F, Kleesiek J, Hellwig B, Rahnenführer J, Rajcsanyi L, Peters T, Hinney A, Placke JM, Sucker A, Paschen A, Becker JC, Livingstone E, Zimmer L, Tasdogan A, Roesch A, Hadaschik E, Schadendorf D, Griewank K, Ugurel S. Lodde GC, et al. Among authors: paschen a. Eur J Cancer. 2024 Oct;210:114295. doi: 10.1016/j.ejca.2024.114295. Epub 2024 Aug 23. Eur J Cancer. 2024. PMID: 39213786 Free article.
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas.
Jansen P, Galetzka W, Lodde GC, Standl F, Zaremba A, Herbst R, Terheyden P, Utikal J, Pföhler C, Ulrich J, Kreuter A, Mohr P, Gutzmer R, Meier F, Dippel E, Weichenthal M, Placke JM, Landsberg J, Möller I, Sucker A, Paschen A, Hadaschik E, Zimmer L, Livingstone E, Schadendorf D, Ugurel S, Stang A, Griewank KG. Jansen P, et al. Among authors: paschen a. Eur J Cancer. 2024 Sep;208:114208. doi: 10.1016/j.ejca.2024.114208. Epub 2024 Jul 6. Eur J Cancer. 2024. PMID: 39018633 Free article.
Clinical and genetic characteristics of BAP1-mutated non-uveal and uveal melanoma.
Matull J, Placke JM, Lodde G, Zaremba A, Utikal J, Terheyden P, Pföhler C, Herbst R, Kreuter A, Welzel J, Kretz J, Möller I, Sucker A, Paschen A, Livingstone E, Zimmer L, Hadaschik E, Ugurel S, Schadendorf D, Thielmann CM, Griewank KG. Matull J, et al. Among authors: paschen a. Front Immunol. 2024 Jun 5;15:1383125. doi: 10.3389/fimmu.2024.1383125. eCollection 2024. Front Immunol. 2024. PMID: 38903495 Free PMC article.
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.
Schuler M, Cuppens K, Plönes T, Wiesweg M, Du Pont B, Hegedus B, Köster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lähnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Schuler M, et al. Among authors: paschen a. Nat Med. 2024 Jun;30(6):1602-1611. doi: 10.1038/s41591-024-02965-0. Epub 2024 Apr 30. Nat Med. 2024. PMID: 38689060 Free PMC article. Clinical Trial.
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.
Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, Maciel LF, Pulido-Vicuña CA, Pollaris L, Seurinck R, Zhao F, Flem-Karlsen K, Damsky W, Chen L, Karagianni D, Cinque S, Kint S, Vandereyken K, Rombaut B, Voet T, Vernaillen F, Annaert W, Lambrechts D, Boecxstaens V, Saeys Y, van den Oord J, Bosisio F, Karras P, Shain AH, Bosenberg M, Leucci E, Paschen A, Rambow F, Bechter O, Marine JC. Pozniak J, et al. Among authors: paschen a. Cell. 2024 Jan 4;187(1):166-183.e25. doi: 10.1016/j.cell.2023.11.037. Cell. 2024. PMID: 38181739 Free article.
119 results